Search academic texts

Information × Registration Number 0220U100242, 0119U100872 , R & D reports Title The value of molecular genetic disturbances in predicting of the response to the second line therapy with tyrosine kinase inhibitors in patients with chronic myeloid leukemia, resistant to imatinib, exposed to ionizing radiation due to Chornobyl PPS accident popup.stage_title Head Diahil Iryna S., Minchenko Jeanne M., Доктор біологічних наук Registration Date 14-01-2020 Organization State Institution "National Research Centre For Radiation Medicine of National Academy of Medical Sciences of Ukraine" popup.description2  Report: 63 pages, 9 tables, 1 figure, 2 appendixes, 79 sources. TYROSINKINAS INHIBITORS, ADDITIONAL CHROMOSOMAL ABERRATIONS, BCR/ABL1 GENE EXPRESSION, INTERLEUKINS, THERAPY RESISTANCE, CHRONIC MYELOID LEUKEMIA Object of study - patients with chronic myeloid leukemia (CML), who require transferring to the second line therapy with tyrosine kinase inhibitors. The aim of the study was to determine the clinical course, dynamics of the fusion BCR/ABL1 gene expression, chromosomal abnormalities, characteristics of the cytokine spectrum in imatinib resistant patients with chronic myeloid leukemia who required transferring to the second line therapy with tyrosine kinase inhibitors. Methods - hematological, cytogenetic, molecular genetic, enzyme immunoassay and statistical. Research results. 59 CML patients were examined, including 7 victims of the Chernobyl power plant accident. According to the results of the conducted researches, the spectrum of clinical, genetic and immunological characteristics of CML patients who were candidates for the appointment of the second line therapy with tyrosine kinase inhibitors was formed, namely: treatment period more than 6 months. before imatinib appointment, the presence of splenomegaly, hyperleukocytosis, intermediate and high Sokal index in the debut of the disease , the presence of the additional chromosome aberrations (ACA), the appearance of new ACA on imatinib therapy, no reduction of the tumor clone or reduction of the BCR/ABL1 fusion gene expression only to the level of complete cytogenetic response during the first year of imatinib therapy, high concentrations of peripheral blood serum interleukin-8, interleukin-1β, interleukin-6, and low concentrations of interleukin-2 and interferon-γ. On the topic of study 11 articles and 5 abstracts of reports at conferences were published, 12 presentations at conferences were made. Field of application: oncology, hematology, genetics. Product Description popup.authors Balan Valentyna V. Dmytrenko Iryna V. Martina Zoya V. Petrusha Oleksandr O. Stupakova Zinaida V. Fedorenko Vira G. Shlyakhtychenko Tetyana Yu. Sholoiko Valentyna V. popup.nrat_date 2020-04-02 Close